Aldeyra Therapeutics, Inc. (ALDX): Long-Term Debt
$15.30M
As of 2025-12-31
-2.2%
3-year compound annual growth
-0.9%
5-year compound annual growth
+27.1%
10-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.30M | 0.0% | 2026-02-27, Balance as of period end |
| 2024-12-31 | $15.30M | 0.0% | 2025-02-28, Balance as of period end |
| 2023-12-31 | $15.29M | -6.4% | 2024-03-07, Balance as of period end |
| 2022-12-31 | $16.34M | +1.8% | 2023-03-09, Balance as of period end |
| 2021-12-31 | $16.04M | 0.0% | 2022-03-17, Balance as of period end |
| 2020-12-31 | $16.04M | 0.0% | 2021-03-11, Balance as of period end |
| 2019-12-31 | $16.04M | n/a | 2020-03-12, Balance as of period end |
| No annual figure between 2017-12-31 and 2019-12-31. | |||
| 2017-12-31 | $1.40M | 0.0% | 2018-03-29, Balance as of period end |
| 2016-12-31 | $1.40M | 0.0% | 2017-03-30, Balance as of period end |
| 2015-12-31 | $1.40M | 0.0% | 2016-03-30, Balance as of period end |
| 2014-12-31 | $1.40M | n/a | 2015-03-23, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Aldeyra Therapeutics, Inc. (ALDX) | 2025-12-31 | $15.30M | 0.0% |
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | $32.09M | 0.0% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $60.04M | -4.2% |
| Scienture Holdings, Inc. (SCNX) | 2024-12-31 | $2.90M | n/a |
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $10.16M | -4.1% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2024-12-31 | $25.00M | -16.7% |
| Eton Pharmaceuticals, Inc. (ETON) | 2024-12-31 | $29.81M | n/a |
| Journey Medical Corp (DERM) | 2025-12-31 | $25.28M | +1.6% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $0 | n/a |
Compare ALDX, HOWL, NWBO, SCNX side by side · Screen every company in Pharmaceutical Preparations ↗